Compare SRPT & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRPT | AZTA |
|---|---|---|
| Founded | 1980 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2000 | 1996 |
| Metric | SRPT | AZTA |
|---|---|---|
| Price | $18.95 | $39.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 24 | 6 |
| Target Price | $21.64 | ★ $37.80 |
| AVG Volume (30 Days) | ★ 2.6M | 956.7K |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.99 | N/A |
| Revenue | ★ $2,198,237,000.00 | $593,821,000.00 |
| Revenue This Year | N/A | $3.53 |
| Revenue Next Year | N/A | $3.98 |
| P/E Ratio | $6.20 | ★ N/A |
| Revenue Growth | ★ 15.58 | N/A |
| 52 Week Low | $14.68 | $15.93 |
| 52 Week High | $24.68 | $46.41 |
| Indicator | SRPT | AZTA |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 51.02 |
| Support Level | $18.38 | $31.51 |
| Resistance Level | $19.71 | $37.49 |
| Average True Range (ATR) | 0.95 | 2.24 |
| MACD | 0.13 | -0.12 |
| Stochastic Oscillator | 62.56 | 47.38 |
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.